# Validity and Reliability of the Scale Assessment and Rating of Ataxia Persian Version Questionnaire

## Zahra Saberi[1]**, Fatemeh Shahabi [2]**, Amin Mansoori [3], Vahid Mardani Kalateh Gheshlagh [4], Habiballah Esmaily [3,5], Masoumeh Hassanpour [6], Maryam Saberi-Karimian [7,8] *

[1] Ear Nose Throat Department, North Khorasan University of Medical Sciences, Bojnurd, Iran.

[2] Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

[3] Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.

[4] Ferdowsi University of Mashhad, Mashhad, Iran.

[5] Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

[6] Department of General Courses, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

[7] Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

[8] Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

## ARTICLE INFO

## ABSTRACT

**Introduction:** The Ataxia Assessment and Rating Scale (SARA) has been validated in English and a standardized tool having translation and modification according to Iranian language and culture was needed. Therefore, we aimed to determine the validity and reliability of the SARA.

**Methods:** This cross-sectional study was conducted among patients with ataxia who were referred to the otolaryngology office from April 2023 to January 2024. The SARA questionnaire consists of 8 objects that have been translated into Persian. Cronbach's alpha coefficient was measured to find the internal consistency. Moreover, the intra-class correlation coefficient (ICC) was calculated to evaluate the test-retest reliability. Furthermore, the content validity ratio (CVR) and the content validity index (CVI) were calculated to assess the content validity.

**Results:** A total of 11 patients with ataxia (aged 48.5±18.8 years) enrolled in the current study. After examining the face validity, the experts did not mention any particular problem. In the content validity, each CVI and CVR index item was equal to one. Cronbach's alpha obtained was equal to 0.893 that indicates a high level of internal consistency of this scale in the first iteration. In the second iteration, this index was obtained as 0.892. In all the items, except the heel shin item, the value of the ICC could not be estimated because the scores in the first and second iterations were the same. ICC for the heel shin item was equal to 0.944 .

**Conclusion:** The Persian version of the SARA questionnaire achieved the necessary validity and reliability and can be used in patients with ataxia to detect the ataxia symptoms and its severity in the country.

** Equal First Author

* Corresponding authors: Maryam Saberi-Karimian, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 99199-91766, Tel: +985138412840, Fax: +985138412840, Email: saberikm@mums.ac.ir; maryamsabery2012@gmail.com .

## Introduction

Ataxia (balance disorder) is defined as impaired muscle control or coordination of voluntary movements including walking or picking up objects. Ataxia may affect the several behaviors and cause complications in speech, eye movements and swallowing (1-3).

Ataxia can occur by damage, change or loss of nerve cells in the cerebellum or the brain in where controls muscle coordination (4). As well, some diseases can damage to the spine and peripheral nerves that joining the cerebellum to the muscles and cause ataxia. Severe head trauma, cerebral palsy, stroke, autoimmune diseases, infection, paraneoplastic syndrome or symptoms resulting from cancer, brain abnormalities, reaction to toxic substances, vitamin E deficiency, vitamin B12 deficiency, thyroid problems (5), and covid-19 infection (6), can be one of the causes of chronic or acute ataxia (7,8).

An immediate treatment strategy can be effective in improving the ataxia patient's symptoms and thereby providing good long-term results, as well as being effective in managing treatable reasons of ataxia and save the patient's life. Therefore, the availability of a tool to measure the neurological manifestations of cerebellar ataxia (such as stance, gait and sitting and etc.) in order to improve the symptoms or measure the effect therapeutic interventions on them could be very beneficial (9).

In 2006, the Scale for the Assessment and Rating of Ataxia (SARA) was initially validated in patients with spinocerebellar ataxia (SCA) and includes 8 items of cerebellar ataxia neurological manifestations (10). The SARA's metric properties have been confirmed in further ataxia disorders including Friedreich ataxia (FRDA), (11), non-SCA ataxia (11), multiple sclerosis patients with ataxia (12), and acute ataxic stroke (13). A great number of studies have also used this tool to evaluate their patients, such as those with cervical dystonia (14), opioid-dependent individuals (15), and even in ultra-rare neurodegenerative diseases like Niemann-Pick type C, the GM2 gangliosidoses, multiple sulfatase deficiency and ataxia telangiectasia (16-19).

Considering ataxia can be the complication of different problems and SARA also has wide applications, therefore we aimed to investigate validity and reliability of the Persian form of the SARA in patients with ataxia.

## Methods

### Questionnaire and scale structure

This questionnaire comprises following items reflecting neurological indexes of cerebellar ataxia: 1-gait, 2-stance, 3-sitting, 4-speech, 5-finger-chase, 6-nose-finger-test, 7-fast alternating hand movements, and 8-heel-shin-slide. The ratings for each item range from 0 (normal, absence of sign) to a maximum of 8 for gait, 6 for stance and speech and 4 for the remaining items. The items of limb coordination are rated for the right and left sides separately and the average of both sides included in the SARA total score. Finally, a sum score of all eight items can be reported that ranging from 0 (no ataxia) to 40 (maximal ataxia or unable to perform), (10).

### Participation

The patients were selected from patients suffering from chronic genetic or non-genetic ataxia with clinical symptoms who referred to the otolaryngology office from April 2023 to January 2024. Patients who received concurrent speech therapy and physiotherapy had to have been on a stable dose and type of treatment for at least 6 weeks prior to their first visit. Likewise, if the patients are taking medicine, they should maintain the same dose over the study period. Dissatisfaction to cooperation, failure to complete the second visit, low vision/hearing loss (which was not corrected using glasses), arthritis or other musculoskeletal disorders were the criteria for exiting and not entering the study. At the first visit, 8 tests included in this questionnaire were performed on selected patients. This study has been approved by the Ethical Committee of Mashhad University of Medical Sciences (IR.MUMS.MEDICAL.REC.1401.693).

## Translation

The forward-backward translation method has been applied for translating the English version questionnaire into Persian. In this way, two English language experts independently translated this English questionnaire to Persian. Formerly, a consolidated Persian version of the above two translations presented. Subsequently, two experts, who had not got the original version of the English questionnaire, translated the Persian version into English and was matched with the original version and the primary Persian version by a research team consisting of clinical experts and English language experts.

## Face validity

This questionnaire was given to the relevant experts (1 neurologist, 1 pediatric neurologist, 2 otolaryngologist and 2 occupational therapist) to measure its appropriateness, grammar, vocabulary, difficulty, and transparency as a quick overall validity of the items. The experts did not mention any specific problems and this questionnaire was prepared in the same way for psychometry.

## Content validity

The content validity was evaluated by 6 experts (1 neurologist, 1 pediatric neurologist, 2 otolaryngologist and 2 occupational therapist) who were asked to the degree to which each item was relevant, simple, clear, and necessary. Content validity index (CVI) to investigated validity was calculated. This index was introduced by Waltz and Bausell (20), and for the calculation of CVI, experts were requested to determine the relevancy score of every item with the following four-part spectrum: completely relevant, relevant, relatively relevant and not relevant. This index is obtained by dividing the number of experts who have chosen completely relevant or relevant options by the total number of the experts. If the index value is <0.7, the item is rejected, if it is between 0.7 and 0.79, it need to be revised, and if it is >0.79, it is acceptable. In this research, each item got score of 1. Content validity ratio (CVR) was designed by

Lawshe (21). Regarding the calculation of CVR, the experts were requested to score each item on a three-point Likert scale as follow: 1-essential, 2-useful but not essential, and 3-not necessary. Based on the number of experts who evaluated the items, the minimum acceptable CVR value was determined according to the specific table. Items for which the calculated CVR value was lower than the desired value according to the total number of experts, should be better to exclude. Based on Lawshe's table with 6 experts, the CVR value of 0.99 was acceptable value for this study. The CVR formula is as follows:

$$\frac{n_e - N/2}{N/2} \qquad (1)$$

in where N= total number of experts, and $n_e$ = the number of experts who have chosen necessary option.
In our study, CVR value of 1 was achieved for each item.

## Reliability testing

It is well known that reliability can be tested by either measuring the Cronbach's alpha for internal consistency or intra-class correlation coefficient (ICC) for test-retest reliability (reproducibility). Commonly accepted values for Cronbach's alpha were defined as excellent for $\alpha > 0.9$ and unacceptable for $\alpha < 0.5$ (22). Test-retest reliability was tested by running a questionnaire to a patient on two separate occasions without any substantial changes in his/her symptoms. A correlation coefficient of 0 indicated no reliability, whereas a value of 1 indicated excellent reliability. To test the reliability, all subjects accepted to reoccurrence for the 2nd visit after at least 2 weeks to measure ataxia by the SARA without receiving any major treatment or changes in symptoms.

## Results

In this research, 11 subjects aged 48.5±18.8 years referred to the otorhinolaryngologist's office participated. 54.5% of these patients were male. Patients were visited with diagnosis of the meniere's disease (n=4, 36.4%), brain trauma (n=1, 9.1%), labyrinthitis (n=2, 18.2%), ataxia telangiectasia (n=1, 9.1%), benign ataxia

**Table1.** Assessment of endpoint: mean/median SARA scores at baseline and after 2 weeks of first visit.

| Patients number | SARA at baseline (mean or median) | SARA after at least 2 weeks (mean or median) |
|---|---|---|
| 1 | 0.13/0 | 0.13/0 |
| 2 | 0.13/0 | 0.13/0 |
| 3 | 2/0.5 | 2/0.5 |
| 4 | 0.13/0 | 0.13/0 |
| 5 | 0.25/0 | 0.25/0 |
| 6 | 0.13/0 | 0.13/0 |
| 7 | 2.63/1.5 | 2.63/1.5 |
| 8 | 0.25/0 | 0.25/0 |
| 9 | 3.75/4 | 3.75/4 |
| 10 | 0.5/0.5 | 0.63/1 |
| 11 | 0.25/0 | 0.25/0 |

(n=2, 18.2%) and sudden sensory neural hearing loss (n=1, 9.1%).

**Discussion**

SARA is known as a reliable and valid measurement method to detect the ataxia severity that is simple to use at the clinic (23, 10). In current research, the translation validity, face validity, content validity and reliability of the SARA Persian version have been assessed in subjects with ataxia. In order to achieve this goal, 11 patients with chronic genetic and non-genetic ataxia referred to the ear, nose and throat clinic were examined with the SARA questionnaire. More recently, disease-specific instruments for some types of ataxia comprising the FARS for Friedreich's ataxia (24), besides the Unified System Multiple Atrophy Rating Scale (25). Numerous systems have been developed for atrophy. The Abbreviated Ataxia Rating Scale (BARS) has been developed by Schmahmann et al., according to a modified form of the International Cooperative Ataxia Rating Scale (ICARS), (26). ICARS has been extensively used as a scale to assess the severity or effectiveness of cerebellar ataxia treatment. Though, its daily use in patients with ataxia is not straight forward due to the assessment items (27). SARA was recently proposed by Schmitz-Hubsch et al. This assessment tool has fewer assessment items comparing with the ICARS and consequently has the advantage of a more convenient daily assessment (11). SARA can be used in other types of ataxia including ataxic stroke (22). There are some studies that evaluated the usefulness of SARA and its comparison with other criteria (28). One study shown that SARA can be useful in patients with ataxic stroke and reported a substantial correlation with modified Barthel index, leaf balance scale and gait status. Therefore, SARA can be a beneficial tool to predict the activity of daily living dependence, gait status and developing treatment plans (23, 29). The use of imprecise terms including "mild, moderate, and severe" is abridged in SARA instrument comparing with ICARS. This suggests that SARA can allow for a more objective assessment without the subjective judgment of the evaluator (9). Though, it is necessary to mention that these tools were developed in the West and validated in English and a standardized tool for Iranians having translation and modification according to Iranian language and culture was needed. As a result, if there is a reliable Persian version of SARA, it can be widely used for all types of ataxia patients in the country in the future. Therefore, we translated SARA into Farsi and checked its validity.

All researchers, experts and translators stated that the Farsi version is as cool to understand as the original form. The present results more highlight the usefulness of SARA for the measureable assessment of ataxia. The results presented here are very similar to those reported in previous studies conducted in ataxic stroke patients (9). As a result, in our study, SARA was confirmed with good reliability and validity in Persian language. Persian SARA can be useful clinically for

disorder assessment or rehabilitation planning.

The CVI was calculated for the investigated validity. In this research, each item scored 1, which means that the statement is acceptable. CVR value of 0.99 was an acceptable value for current study. Also, in this study, the patients were requested to check the SARA index at the beginning, and return after two weeks without receiving any special treatment for re-examination, and the results show that the scores of the patients are the same in these two examinations. 10 of our 11 patients had the same first and second visit scores, and only one patient had a score of 0.5/0.5 in the first visit and 0.63/0 in the second visit.

## Conclusion

The Persian version of the SARA questionnaire can be used clinically as a reliable and valid instrument for disorder assessment and rehabilitation planning in patients with ataxia.

## Funding

## Conflict of Interest

The authors confirm no conflicts of interest.

## Acknowledgments

## References

1. Choi SW, Han N, Jung SH, Kim HD, Eom MJ, Bae HW. Evaluation of ataxia in mild ischemic stroke patients using the scale for the assessment and rating of ataxia (SARA). Annals of rehabilitation medicine. 2018 Jun 27;42(3):375-83.

2. Mariotti C, Fancellu R, Di Donato S. An overview of the patient with ataxia. Journal of neurology. 2005 May;252:511-8.

3. Marsden J, Harris C. Cerebellar ataxia: pathophysiology and rehabilitation. Clinical rehabilitation. 2011 Mar;25(3):195-216.

4. Sporns O. Networks of the Brain. MIT press; 2016 Feb 12

5. Ercoli T, Defazio G, Muroni A. Cerebellar syndrome associated with thyroid disorders. The Cerebellum. 2019 Oct;18(5):932-40.

6. Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19: a case report and systematic review. Journal of Neurology. 2021 Oct 1:1-32.

7. Pedroso JL, Vale TC, Braga-Neto P, Dutra LA, França MC, Teive HA, et al. Acute cerebellar ataxia: differential diagnosis and clinical approach. Arquivos de neuro-psiquiatria. 2019;77:184-93.

8. Ashizawa T, Xia G. Ataxia. Continuum: Lifelong Learning in Neurology. 2016 Aug 1;22(4):1208-26.

9. Yabe I, Matsushima M, Soma H, Basri R, Sasaki H. Usefulness of the Scale for Assessment and Rating of Ataxia (SARA). Journal of the neurological sciences. 2008 Mar 15;266(1-2):164-6.

10. Schmitz-Hubsch T, Du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006 Jun 13;66(11):1717-20.

11. Weyer A, Abele M, Schmitz-Hübsch T, Schoch B, Frings M, Timmann D, et al. Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Movement disorders: official journal of the Movement Disorder Society. 2007 Aug 15;22(11):1633-7.

12. Salcı Y, Fil A, Keklicek H, Çetin B, Armutlu K, Dolgun A, et al. Validity and reliability of the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) in multiple sclerosis patients with ataxia. Multiple sclerosis and related disorders. 2017 Nov 1;18:135-40.

13. Yamauchi K, Kumagae K, Goto K, Hagiwara R, Uchida Y, Harayama E, et al. Predictive validity of the scale for the assessment and rating of ataxia for medium-term functional status in acute ataxic stroke. Journal of Stroke and Cerebrovascular Diseases. 2021 Apr 1;30(4):105631.

14. Boyce MJ, McCambridge AB, Bradnam LV, Canning CG, Mahant N, Chang FC, et al. A cross-sectional study of walking, balance and upper limb assessment scales in people with cervical dystonia. Journal of Neural Transmission. 2021 Nov;128:1663-75.

15. Knuijver T, Schellekens A, Belgers M, Donders R, van Oosteren T, Kramers K, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction. 2022 Jan;117(1):118-28.

16.     Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill GC, et al. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials. 2021 Dec;22:1-5.

17.     Saberi-Karimian M, Beyraghi-Tousi M, Jamialahmadi T, Sahebkar A. The positive short-term effect of dexamethasone on ataxia symptoms in a patient with ataxia-telangiectasia: A case report. Clinical Case Reports. 2022 May;10(5):e05895.

18. Saberi-Karimian M, Houra M, Jamialahmadi T, Sarvghadi P, Nikbaf M, Akhlaghi S, et al. The effects of N-Acetyl-L-Leucine on the improvement of symptoms in a patient with multiple sulfatase deficiency. The Cerebellum. 2023 Dec;22(6):1250-6.

19.     Beyraghi-Tousi M, Sahebkar A, Houra M, Sarvghadi P, Jamialahmadi T, Bagheri R, et al. Efficacy and safety of N-acetyl-L-leucine in patients with ataxia telangiectasia: A randomized, double-blind, placebo-controlled, crossover clinical trial. European Journal of Paediatric Neurology. 2024 May 1;50:57-63.

20. Waltz CF, Bausell BR. Nursing research: design statistics and computer analysis. Davis Fa; 1981 Jan 1.

21. Lawshe CH. A Quantitative Approach to Content Validity. Personnel psychology/Berrett-Koehler Publishers. 1975.

22. Carvajal A, Centeno C, Watson R, Martínez M, Rubiales AS. How is an instrument for measuring health to be validated?. InAnales del sistema sanitario de Navarra 2011 Jan 1 (Vol. 34, No. 1, pp. 63-72).

23. Song TA, Niu HX, Lu ZH, Yuan GA, Lu JM, Shi CH, et al. Reliability and validity of the Chinese version of the Scale for Assessment and Rating of Ataxia. Chinese medical journal. 2013 Jun 5;126(11):2045-8.

24.     Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology. 2005 Apr 12;64(7):1261-2.

25.     Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, et al. Development and validation of the unified multiple system atrophy rating scale (UMSARS). Movement Disorders. 2004 Dec;19(12):1391-402.

26.     Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Movement disorders. 2009 Sep 15;24(12):1820-8.

27.     Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. Journal of the neurological sciences. 1997 Feb 12;145(2):205-11.

28.     Braga-Neto P, Godeiro-Junior C, Dutra LA, Pedroso JL, Barsottini OG. Translation and validation into Brazilian version of the Scale of the Assessment and Rating of Ataxia (SARA). Arquivos de neuro-psiquiatria. 2010;68:228-30.

29.  Kim BR, Lim JH, Lee SA, Park S, Koh SE, Lee IS, et al. Usefulness of the Scale for the Assessment and Rating of Ataxia (SARA) in ataxic stroke patients. Annals of Rehabilitation Medicine. 2011 Dec 30;35(6):772-80.

**تاریخ** ................. **نوبت/ویزیت :** .................                    نام/کد بیمار ........................ نام/کد کاردرمانگر.....................

# معیار ارزیابی و طبقه بندی آتاکسی به روش پرسشنامه SARA

| ۱. راه رفتن | ۲. ایستادن |
|---|---|

**۲. ایستادن**

از داوطلب خواسته می شود بایستد (۱) در حالت طبیعی، (۲) در حالی که پاها به موازات هم قرار گرفته اند (انگشتان شست یکدیگر را لمس می کنند) و *(۳) در حالتیکه پاها پشت سر هم قرار دارند {(هر دو پا روی یک خط هستند، فاصله ای بین پاشنه و انگشت وجود ندارد، (حرکت گردوشکن)}. داوطلب نباید کفش بپوشد، و باید چشم ها باز باشند. برای هر وضعیت، سه آزمایش مجاز است. بهترین آزمایش نمره داده شود.

۰- نرمال است، قادر به ایستادن در وضعیت تاندم (heels to toes) برای بیش از ۱۰ ثانیه است

۱- قادر به ایستادن با پاها کنار هم و بدون تاب خوردن است، اما نه به حالت تاندم برای بیش از ۱۰ ثانیه

۲- قادر به ایستادن در حالت پاها درکنار هم برای بیش از ۱۰ ثانیه می باشد، اما فقط با نوسان

۳-قادر به ایستادن برای بیش از ۱۰ ثانیه بدون کمک در موقعیت طبیعی است، اما با پاهای کنار هم خیر

۴- قادر به ایستادن برای بیش از ۱۰ ثانیه در موقعیت طبیعی تنها با کمک متناوب است

۵- قادر به ایستادن برای بیش از ۱۰ ثانیه در موقعیت طبیعی تنها با کمک دایمی یک بازو است

۶- حتی با کمک دایم یک بازو، قادر به ایستادن برای بیش از ۱۰ ثانیه نیست

**۱. راه رفتن**

از داوطلب (۱) خواسته می شود تا در مسافتی ایمن و موازی با یک دیوار یک نیم دور راه برود (به دور خود بچرخد در جهت مخالف راه رفتن) و *(۲) بدون کمک پشت سر هم (حرکت گردوشکن) راه برود

۰- نرمال است، بدون هیچ مشکلی در راه رفتن، چرخش و پشت سر هم راه رفتن (حداکثر یک حرکت اشتباه مجاز است)

۱- مشکل کمی دارد، فقط هنگام ۱۰گام متوالی پشت سر هم راه رفتن، قابل مشاهده است

۲- به طور واضح غیر طبیعی است، راه رفتن پشت سر هم بیش از ۱۰ قدم ممکن نیست

۳- بطور قابل توجهی در چرخش مشکل دارد، اما بدون کمک

۴- کمک زیاد و متناوب دیوار مورد نیاز است

۵- کمک بسیار زیاد یعنی حمایت دائمی با یک عصا یا حمایت اندکی از یک بازو مورد نیاز است.

۶- راه رفتن بیش از ۱۰ متر فقط با کمک زیاد (دو عصای مخصوص یا کالسکه یا شخص همراه)

۷- راه رفتن کمتر از ۱۰ متر فقط با کمک زیاد (دو عصای مخصوص یا کالسکه یا شخص همراه)

۸- قادر به راه رفتن نیست، حتی در حالتی که کمک می شود

| نمره | نمره |
|---|---|

| ۴- اختلال گفتار | ۳- نشستن |
|---|---|

**۴- اختلال گفتار**

گفتار در هنگام مکالمه عادی، ارزیابی می شود.

۰- نرمال است

۱- اختلال در گفتار به ذهن خطور می کند

۲- گفتار مختل شده، اما درک آن آسان است

۳- درک کلمات گاها"دشوار است

۴- درک بسیاری از کلمات دشوار است

۵- تنها کلمات منفرد قابل درک هستند

۶-گفتار نامفهوم / anarthria

**۳- نشستن**

از داوطلب خواسته می شود بدون کمک پا، با چشم باز و بازوهای کشیده به جلو، روی تخت معاینه بنشیند.

۰- نرمال است، بدون هیچ مشکلی در نشستن برای بیش از ۱۰ ثانیه

۱- مشکل کمی دارد، یعنی نوسان متناوب

۲- نوسان مداوم دارد، اما قادر به نشستن برای بیش از ۱۰ ثانیه بدون کمک می باشد

۳- فقط با کمک متناوب قادر به نشستن برای بیش از ۱۰ ثانیه است

۴- بیش از ۱۰ ثانیه بدون کمک مداوم نمی تواند بنشیند

| نمره | نمره |
|---|---|

**6- تست انگشت-بینی**

دارای رتبه بندی جداگانه برای هر طرف است

داوطلب به راحتی می نشیند. در صورت لزوم، کمک پا و تنه مجاز است. از داوطلب خواسته می شود تا به طور مکرر با انگشت خود به سمت انگشت معاینه کننده که در مقابل داوطلب و در حدود 90٪ از دسترسی داوطلب است، اشاره کند. عملکرد متوسط حرکات باتوجه به دامنه لرزش حرکتی (کینتیک ترمور)درجه بندی شود.

0- ترمور ندارد

1- ترمور با دامنه کمتر از 2 سانتی متر

2- ترمور با دامنه کمتر از 5 سانتی متر

3- ترمور با دامنه بیشتر از 5 سانتی متر

4- قادر به انجام 5 حرکت اشاره ای نیست

**5- تعقیب انگشت**

برای هر طرف جداگانه رتبه بندی شده است.

داوطلب به راحتی می نشیند. در صورت لزوم، کمک پا و تنه مجاز است. معاینه کننده در جلوی داوطلب نشسته و 5 حرکت اشاره ناگهانی را بصورت متوالی و سریع در جهات غیر قابل پیش بینی در سطح مقطع فرونتال، در محدوده ایکه داوطلب به 50٪ از آن دسترسی یابد انجام می دهد. دامنه حرکات 30 سانتی متر و با فرکانس 1 حرکت در هر 2 ثانیه است. از داوطلب خواسته می شود که حرکات را با انگشت اشاره خود، هرچه سریعتر و دقیق تر دنبال کند. عملکرد متوسط 3 حرکت آخر نمره داده شود.

0- عدم وجود دیسمتری

1- دیسمتری، under/ overshooting target کمتر از 5 سانتی متر

2- دیسمتری، under/ overshooting target کمتر از 15 سانتی متر

3- دیسمتری، under/ overshooting target بیشتر از 15 سانتی متر

4- انجام 5 حرکت اشاره ای امکان پذیر نیست

| نمره | نمره دست راست: | نمره دست چپ: | نمره | نمره دست راست: | نمره دست چپ: |
|---|---|---|---|---|---|
| میانگین هر دو طرف (چپ+ راست)/2 | | | میانگین هر دو طرف (چپ+ راست)/2 | | |

**8- لغزش پاشنه پا**

دارای رتبه بندی جداگانه برای هر طرف است.

داوطلب روی تخت معاینه دراز کشیده، بدون اینکه پاهایش را ببیند. از داوطلب خواسته می شود یک پا را بلند کند، پاشنه را در امتداد ساق پا تا مچ پا به پایین بلغزاند و پا را روی تخت معاینه قرار دهد. این کار، 3 بار انجام شود. حرکات لغزشی به پایین باید در عرض 1 ثانیه انجام گیرد. اگر داوطلب پا را در هر سه آزمایش، بدون تماس با ساق پا به سمت پایین کشید، نمره 4 می گیرد.

0- نرمال است

1- کمی غیر طبیعی است، تماس با ساق پا حفظ شده است

2- به طور واضح غیر طبیعی است، تماس با ساق در طی 3 سیکل، تا 3 بار از بین می رود

3- بشدت غیر طبیعی است در طی 3 سیکل، 4 بار یا بیشتر تماس با ساق از بین می رود

4- انجام این کار، امکان پذیر نیست

**7- حرکات دست متناوب سریع**

دارای رتبه بندی جداگانه برای هر طرف است.

داوطلب به راحتی می نشیند. در صورت لزوم ، کمک پا و تنه مجاز است.. از داوطلب خواسته می شود که 10 دوره روی زانوی مقابل قرار دهد. از داوطلب خواسته می شود که پشت سرهم پروناسیون وسوپینیشن را درحد ممکن تکرار کند (به طور متناوب دستش را به حالت پرو نیشن وسپس سوپینیشن بچرخاند و این حرکت را ده بار پشت سر هم تکرار کند). حرکت توسط معاینه کننده با سرعت تقریبی10 چرخه در 7 ثانیه نشان داده می شود. زمان دقیق اجرای حرکات باید مورد نظر قرار گیرد.

0- نرمال است، بدون بی نظمی (کمتر از 10 ثانیه انجام می شود)

1- کمی نامنظم (کمتر از 10 ثانیه انجام می شود)

2- بطور مشخص نامنظم است، یعنی تشخیص حرکات منفرد و وقفه های مربوطه دشوار است اما در کمتر از 10 ثانیه انجام می شود

3- حرکات بسیار نامنظم است، تشخیص حرکات منفرد و وقفه های مربوطه دشوار است و در بیشتر از 10 ثانیه انجام می شود

4- انجام 10 سیکل امکان پذیر نیست

| نمره | نمره پای راست: | نمره پای چپ: | نمره | نمره دست راست: | نمره دست چپ: |
|---|---|---|---|---|---|
| میانگین هر دو طرف (چپ+ راست)/2 | | | میانگین هر دو طرف (چپ+ راست)/2 | | |

**نمره کل:** [ ]

نمره کل، حاصل مجموع خانه های خاکستری رنگ است. *heels to toes